Could a cholesterol drug slow ovarian cancer? small study tests the idea.
NCT ID NCT04457089
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 32 times
Summary
This early-phase study tested whether adding simvastatin, a common cholesterol-lowering drug, to standard chemotherapy could help control platinum-sensitive ovarian cancer. 18 women with recurrent disease took part. The main goal was to see if patients could stick with the simvastatin regimen, and researchers also tracked cancer progression and CA125 levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.